Assisted reproductive technologies and the pitfalls of unregulated biomedical innovation.
This Article suggests that the time has come to reconsider the safety and effectiveness of fertility drugs in order to combat some of the continuing problems arising from the overly aggressive use of assisted reproductive technologies, especially the health hazards associated with multifetal pregnancies. After critically assessing the arguments made by some commentators about the power of malpractice law to curb any abuses of fertility clinics and specialists, the Article concludes that the Food and Drug Administration should consider restricting or withdrawing pharmaceutical products used to induce ovulation. Although such a drastic move would not prevent the continued use of in vitro fertilization and other advanced fertility treatments, it would dramatically reduce the frequency of multifetal pregnancies, and it should not run afoul of any constitutional protections of procreative liberty.
Noah
Lars
L
University of Florida, USA.
D004624:Embryo Transfer; D005260:Female; D005299:Fertility Agents / Q000009:adverse effects; D033161:Government Regulation; D006801:Humans; D008318:Malpractice; D011247:Pregnancy; D011272:Pregnancy, Multiple; D027724:Reproductive Techniques, Assisted / Q000009:adverse effects* / Q000331:legislation & jurisprudence*; D014481:United States; D014486:United States Food and Drug Administration
D005299:Fertility Agents